Furui Medical's net profit is expected to grow by 36% to 150 million yuan in 2025, with Chairman Wang Guanyi's salary at 1.79 million yuan.

robot
Abstract generation in progress

Rui Finance Liu Zhiying On March 24, Furuimedical (SZ300049) released its 2025 annual report.

In 2025, Furuimedical generated operating revenue of 1.595 billion yuan, up 18.26% year over year. Net profit attributable to shareholders of the listed company was 154 million yuan, up 36.02% year over year. Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 135 million yuan, up 14.34% year over year.

By product category, in 2025, Furuimedical’s devices and technologies recorded operating revenue of 1.134 billion yuan, up 23.48%; pharmaceuticals recorded operating revenue of 385 million yuan, up 0.58%; medical services and others recorded operating revenue of 77 million yuan, up 58.88%.

According to RuiCaishi, Chairman Wang Guanyi of Furuimedical is a post-1970s executive who served as the company’s general manager at age 28.

According to the materials, Wang Guanyi holds Chinese nationality, has no permanent overseas residency rights, is male, born in February 1970, has a college degree, and is a senior economist. From February 1993 to May 1995, he served as the manager of Inner Mongolia Mengdian Non-Destructive Testing Technology Co., Ltd.; from May 1995 to November 1998, he served as deputy general manager of Beijing Fumaitel; from November 1998 to February 2011, he served as the company’s general manager; from June 2005 to present, he has served as the company’s chairman.

Eastmoney data shows that from 2021 to 2025, Wang Guanyi’s compensation was 709.4 thousand yuan, 813.6 thousand yuan, 300.0 thousand yuan, 1.63 million yuan, and 1.794 million yuan, respectively.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin